NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

At NCCN 2026, Dr. Charles Peyton emphasized patient engagement and shared decision-making as expanding treatment options reshape bladder cancer care. At the 2026 NCCN Annual Meeting, Dr. Charles ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Therapeutic options to treat intermediate-risk and BCG-unresponsive bladder cancer, such as medications and ablative therapies, are expanding, and novel PET tracers enable improved diagnosis and ...

Before the discovery of newer options and combinations, chemotherapy that included platinum medications like cisplatin or carboplatin was the first choice, says Christopher Wee, MD, a genitourinary ...

Jimi Stewart, a rollerblading enthusiast from Austin, Texas, was diagnosed with a type of non-muscle invasive bladder cancer at age 39 after noticing an "alarming" amount of blood in his urine.

The FDA will review the expansion of Anktiva plus BCG to patients with papillary-only bladder cancer, with a final decision expected by Jan.6, 2027. ・The acceptance reversed last year’s FDA refusal-to ...

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...